Celldex Therapeutics, Inc. (CLDX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$30.10+0.70%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put CLDX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisManagement screens weak on margins, the balance sheet.
View ManagementThis stock is volatile — it swings about 1% on a typical day and fell roughly 39% in its worst 12-month stretch.
View RiskCLDX’s case rests on advancing barzolvolimab through Phase 3 and toward commercialization. Revenue growth is not reported; the latest quarterly result beat EPS estimates. The shares lack a clean valuation multiple; peer multiples imply a price about 51% above where it trades. The price is roughly in line with forecast growth. Safety concerns could delay Phase 3 trials; our model puts the next-quarter miss probability at 36%. Management is behind on a stated commitment, putting the thesis on watch. This read is provisional.
Trailing returns as of 2026-10-30. CLDX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering CLDX (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for CLDX in the last 4 months.
Continue this research
Compare CLDX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CLDX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CLDX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance barzolvolimab Phase 3 trials and prepare for commercialization
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $30.10
The last 12 months of price, then the range of analyst 12-month targets from today’s $30.10.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Price target increase reflects confidence in barzolvolimab progress.
Advances: Advance barzolvolimab Phase 3 trials and prepare for commercialization
Price target increase reflects confidence in barzolvolimab progress.
Advances: Advance barzolvolimab Phase 3 trials and prepare for commercialization
Positive Phase 3 results support commercialization plans.
Threatens: Advance barzolvolimab Phase 3 trials and prepare for commercialization
Safety concerns may delay barzolvolimab Phase 3 trials.
Advances: Advance barzolvolimab Phase 3 trials and prepare for commercialization
Positive trial results support commercialization efforts.
